申请人:Respivert, Ltd.
公开号:US10358445B2
公开(公告)日:2019-07-23
The present invention relates to respiratory formulations comprising a compound of formula (I):
and use of said compounds and compositions in treatment, for example in the treatment of an inflammatory disease or a respiratory disorder, in particular an inflammatory mediated and/or virally mediated respiratory disorder such as asthma and COPD or the treatment or prevention of viral infection, for example infection by influenza virus, rhinovirus or RSV. The invention also extends to certain novel compounds of formula (I).
本发明涉及包含式(I)化合物的呼吸制剂:
以及所述化合物和组合物在治疗中的应用,例如在治疗炎症性疾病或呼吸系统疾病,特别是炎症介导和/或病毒介导的呼吸系统疾病,如哮喘和慢性阻塞性肺病,或治疗或预防病毒感染,例如流感病毒、鼻病毒或 RSV 感染中的应用。本发明还涉及某些新型的式 (I) 化合物。